Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Hydroxyprogesterone Caproate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
5 min read
Hydroxyprogesterone Caproate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
5 September 2023
This article summarized the latest R&D progress of Hydroxyprogesterone Caproate, the Mechanism of Action for Hydroxyprogesterone Caproate, and the drug target R&D trends for Hydroxyprogesterone Caproate.
Read →
Abata Therapeutics Unveils ABA-201, a New Development Candidate for Type 1 Diabetes Management
Latest Hotspot
4 min read
Abata Therapeutics Unveils ABA-201, a New Development Candidate for Type 1 Diabetes Management
5 September 2023
Abata Therapeutics reveals the second development candidate, ABA-201, designed for the management of Type 1 Diabetes
Read →
Targeted immune modulator: TNF inhibitor
Targeted immune modulator: TNF inhibitor
5 September 2023
Tumor Necrosis Factor (TNF) is a protein produced by immune cells in the human body. It plays a crucial role in regulating inflammation and immune responses.
Read →
Overview of BeiGene’s Pipeline | R&D Progress
R&D Pipeline
5 min read
Overview of BeiGene’s Pipeline | R&D Progress
5 September 2023
BeiGene Ltd. is a global biotechnology company founded in 2010 and is one of China's leading innovative pharmaceutical companies.
Read →
AusperBio Declares FDA Approval of IND Application for AHB-137 for Treating Chronic Hepatitis B
Latest Hotspot
3 min read
AusperBio Declares FDA Approval of IND Application for AHB-137 for Treating Chronic Hepatitis B
5 September 2023
AusperBio Therapeutics, Inc.have declared today that the FDA has sanctioned the IND application for testing of AHB-137 in clinics.
Read →
Frovatriptan Succinate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Frovatriptan Succinate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
5 September 2023
This article summarized the latest R&D progress of Frovatriptan Succinate, the Mechanism of Action for Frovatriptan Succinate, and the drug target R&D trends for Frovatriptan Succinate.
Read →
The Advanced Journey of Glycemic Control Star - DPP-4 Inhibitors
The Advanced Journey of Glycemic Control Star - DPP-4 Inhibitors
5 September 2023
DPP-4 inhibitors enhance the incretin effect by inhibiting DPP-4.
Read →
Overview of Bayer Pipeline|R&D Progress
R&D Pipeline
4 min read
Overview of Bayer Pipeline|R&D Progress
5 September 2023
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is Germany's largest industrial group.
Read →
Improvement in Asthma Patients One Year After Mepolizumab Treatment
Latest Hotspot
4 min read
Improvement in Asthma Patients One Year After Mepolizumab Treatment
5 September 2023
Data analysis from a sample of 822 patients reveals noticeable mepolizumab in symptomatology among Mepolizumab-treated adult asthma sufferers a year post-treatment, regardless of the existence of concomitant medical conditions.
Read →
Unleashing the Power of Fremanezumab-VFRM: A Comprehensive Review on R&D Breakthroughs
Drug Insights
5 min read
Unleashing the Power of Fremanezumab-VFRM: A Comprehensive Review on R&D Breakthroughs
5 September 2023
This article summarized the latest R&D progress of Fremanezumab-VFRM, the Mechanism of Action for Fremanezumab-VFRM, and the drug target R&D trends for Fremanezumab-VFRM.
Read →
Review and Recent Advancements in Aldosterone Antagonists
Review and Recent Advancements in Aldosterone Antagonists
5 September 2023
Aldosterone can enhance the sensitivity of vascular smooth muscle to vasoconstrictive substances, indirectly causing other diseases in the body.
Read →
Overview of Arvinas’s Drug Pipeline | R&D Progress | Drug Target
R&D Pipeline
4 min read
Overview of Arvinas’s Drug Pipeline | R&D Progress | Drug Target
5 September 2023
Arvinas, Inc. is a biopharmaceutical company that was founded in 2013 and is based in Connecticut, United States.
Read →